Rongzhang Chen, Chen Feng, Lujun Chen, Xiao Zheng, Weiwei Fang, Shaoxian Wu, Xinran Gao, Can Chen, Jiayi Yang, Yue Wu, Yuanyuan Chen, Panpan Zheng, Nan Hu, Maoling Yuan, Yuanyuan Fu, Hanjie Ying, Jun Zhou, Jingting Jiang
Both preclinical and clinical studies have extensively proven the effectiveness of TIGIT inhibitors in tumor immunotherapy. However, it has been discovered that the presence of CD226 on tumor-infiltrating lymphocytes is crucial for the effectiveness of both anti-TIGIT therapy alone and when combined with anti-PD-1 therapy for tumors. In our investigation, we observed that cordycepin therapy significantly augmented the expression of the Cd226 gene. As a result, it was hypothesized that cordycepin therapy could enhance the effectiveness of anti-TIGIT therapy...
November 21, 2023: International Immunopharmacology